Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an intravenous solution for infusion use. It is indicated for the treatment of metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan Accord is a topoisomerase I inhibitor used in the management of colorectal cancer and related disease states.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine therapy. Advanced colorectal cancer: used as part of combination regimens to control tumor growth. Colorectal adenocarcinoma: administered intravenously to inhibit tumor cell replication.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: managed with standard anti‑emetics. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness. - Anemia: decreased red blood cell count.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, requiring urgent care. - Intestinal perforation: rare but life‑threatening gastrointestinal injury. - Severe allergic reactions: anaphylaxis or hypersensitivity. - Hepatic toxicity: elevated liver enzymes or jaundice. - Severe dehydration: secondary to profuse diarrhea. - Secondary malignancies: rare long‑term risk.

Before initiating therapy, clinicians should evaluate several safety parameters.

Monitor blood counts: watch for neutropenia and anemia. Assess liver function: adjust dose in hepatic impairment. Maintain hydration: ensure adequate fluid intake to mitigate diarrhea. Pregnancy and lactation: use only if potential benefit justifies risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several drug classes that may alter its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase exposure and toxicity. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - Concurrent topoisomerase I inhibitors: additive bone‑marrow suppression. - Live vaccines: contraindicated due to immunosuppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Antiemetics (e.g., ondansetron): may affect metabolism and require dose adjustment.